New data seems to show that GLP-1 medications like semaglutide, the active ingredient in popular drugs Ozempic and Wegovy, ...

Eli Lilly recently reported detailed late-phase trial results showing that people with obesity were able to maintain long-term weight loss after switching to oral Foundayo or lower-dose Zepbound, ...

A study led by researchers at Imperial College London, through the NCD Risk Factor Collaboration (NCD-RisC), and published in ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented interim results from a Phase 1/2a clinical trial of ARO-INHBE, the company’s investigational RNA interference (RNAi) therapeutic being ...

This is part of a series about new obesity drugs that are transforming patients’ lives, dividing medical experts, and spurring one of the biggest business battles in years. Read more about The Obesity ...

Participants in Eli Lilly’s TRIUMPH-1 trial lost an average of roughly 85 pounds on the highest dose of retatrutide, an ...

Eli Lilly’s LLY 38% revenue growth and 61% non-GAAP EPS growth in the second quarter were above consensus expectations. Management raised 2025 guidance to ranges of $60 billion-$62 billion in revenue ...

Wave Life Sciences presented promising preclinical data at the American Diabetes Association's 85th Annual Scientific Sessions, highlighting WVE-007, a GalNAc-siRNA therapy targeting INHBE as a ...

As Eli Lilly (NYSE: LLY) and Novo Nordisk (Nasdaq Copenhagen: NOVO-B) scramble to bring an oral glucagon-like peptide 1 (GLP-1) receptor agonist to market for obesity, a much smaller potential rival ...